Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Level of markers of neurodegeneration in patients with ocular ischemic syndrome

Halidjan Kamilov, Munirahon Kasimova, Dilbar Makhkamova

. 2014 ; 7 (2) : 46-49.

Jazyk angličtina Země Česko Médium elektronický zdroj

Typ dokumentu srovnávací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc15010759

The purpose of this study was to investigate the content neurospecific markers protein S-100 and neuroenolaza in blood serum and tear fluid of patients with ocular ischemic syndrome. Material and methods. We observed 43 patients aged 57 to 79 years, mean age 67.3 ± 2.7 years. Control group consisted of 11 volunteers without ophthalmic symptoms. The main group consisted of 32 patients with OIS. The neurospecific proteins S100 and NSE were investigated in blood serum and tear fluid. Results. The study found that in patients of the control group the content of protein were within the normal range: S -100 in the tear fluid – 0,0662 ± 0,00335 mkg/l, in the blood serum 0,0508 ± 0,00241 mkg/l. In patients of the main group the indicators of protein in the tear fluid were elevated in all patients - 3,12 ± 0,246 mkg/l ( p<0.005). The normal evels in blood serum of marker S-100 was in 30 patients - 0,0589 ± 0,00303 mkg/l, while, in 2 patients protein S-100 were raised and averaged 0,2175±0,00725 mkg/l. It was found that in patients of the control group content of protein NSE in the tear fluid and blood serum were within normal values - 15,86 ± 0,148 Ng/ml, 15,60 ± 0,202 Ng/ml respectively. In the main group the amount of protein NSE tended to increase in the tear fluid in 23 patients and averaged 33,012 ± 3,2626 Ng/ml (p<0.005), a significant decrease the quantity of protein was observed in 9 patients, which amounted to 5,166 ± 0,8301 Ng/ml. At normal levels in the blood serum protein NSE detected in 30 patients and averaged 14,48 ± 0,263 Ng/ml, whereas, in 2 patients there was a significant increase of content of protein NSE and was 27,47 ± 3,068 Ng/ml. Conclusions. Thus, changes in the concentration of S100 and neuroenolaza in the tear fluid in patients with ocular ischemic European Medical, Health and Pharmaceutical Journal ISSN 1804-5804 syndrome allow to identify as marker of nerve cells damage of the eye, contributing to the definition in conjunction with other signs of stage and etiology of the disease.

Level of markers of neurodegeneration in patients with ocular ischemic syndrome [elektronický zdroj] /

Citace poskytuje Crossref.org

Bibliografie atd.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc15010759
003      
CZ-PrNML
005      
20190528140509.0
007      
cr|cn|
008      
150322s2014 xr a fs 000 0|eng||
009      
eAR
024    7_
$a 10.12955/emhpj.v7i2.522 $2 doi
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a xr
100    1_
$a Kamilov, Halidjan $u Tashkent Institute of Postgraduate Medical Education, Tashkent, Uzbekistan
245    10
$a Level of markers of neurodegeneration in patients with ocular ischemic syndrome $h [elektronický zdroj] / $c Halidjan Kamilov, Munirahon Kasimova, Dilbar Makhkamova
504    __
$a Literatura
520    9_
$a The purpose of this study was to investigate the content neurospecific markers protein S-100 and neuroenolaza in blood serum and tear fluid of patients with ocular ischemic syndrome. Material and methods. We observed 43 patients aged 57 to 79 years, mean age 67.3 ± 2.7 years. Control group consisted of 11 volunteers without ophthalmic symptoms. The main group consisted of 32 patients with OIS. The neurospecific proteins S100 and NSE were investigated in blood serum and tear fluid. Results. The study found that in patients of the control group the content of protein were within the normal range: S -100 in the tear fluid – 0,0662 ± 0,00335 mkg/l, in the blood serum 0,0508 ± 0,00241 mkg/l. In patients of the main group the indicators of protein in the tear fluid were elevated in all patients - 3,12 ± 0,246 mkg/l ( p<0.005). The normal evels in blood serum of marker S-100 was in 30 patients - 0,0589 ± 0,00303 mkg/l, while, in 2 patients protein S-100 were raised and averaged 0,2175±0,00725 mkg/l. It was found that in patients of the control group content of protein NSE in the tear fluid and blood serum were within normal values - 15,86 ± 0,148 Ng/ml, 15,60 ± 0,202 Ng/ml respectively. In the main group the amount of protein NSE tended to increase in the tear fluid in 23 patients and averaged 33,012 ± 3,2626 Ng/ml (p<0.005), a significant decrease the quantity of protein was observed in 9 patients, which amounted to 5,166 ± 0,8301 Ng/ml. At normal levels in the blood serum protein NSE detected in 30 patients and averaged 14,48 ± 0,263 Ng/ml, whereas, in 2 patients there was a significant increase of content of protein NSE and was 27,47 ± 3,068 Ng/ml. Conclusions. Thus, changes in the concentration of S100 and neuroenolaza in the tear fluid in patients with ocular ischemic European Medical, Health and Pharmaceutical Journal ISSN 1804-5804 syndrome allow to identify as marker of nerve cells damage of the eye, contributing to the definition in conjunction with other signs of stage and etiology of the disease.
650    _2
$a oční nemoci $x patologie $7 D005128
650    12
$a biologické markery $x analýza $x krev $7 D015415
650    _2
$a proteiny S100 $x analýza $x krev $7 D009418
650    _2
$a fosfopyruváthydratasa $x analýza $x krev $7 D010751
650    _2
$a slzy $x chemie $7 D013666
650    _2
$a ischemie $x diagnóza $x patofyziologie $7 D007511
650    _2
$a atrofie optického nervu $x diagnóza $x patofyziologie $7 D009896
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
653    10
$a oční ischemický syndrom
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Kasimova, Munirahon $u Tashkent Institute of Postgraduate Medical Education, Tashkent, Uzbekistan
700    1_
$a Makhkamova, Dilbar $u Tashkent Institute of Postgraduate Medical Education, Tashkent, Uzbekistan
773    0_
$t European medical, health and pharmaceutical journal $x 1804-5804 $g Roč. 7, č. 2 (2014), s. 46-49 $w MED00177703
856    41
$u https://ojs.journals.cz/index.php/EMHPJ/issue/view/54 $y plný text volně přístupný
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20150321103405 $b ABA008
991    __
$a 20190528140634 $b ABA008
999    __
$a ok $b bmc $g 1068210 $s 893597
BAS    __
$a 3 $a 4 $a PRD
BMC    __
$a 2014 $b 7 $c 2 $d 46-49 $i 1804-5804 $m European Medical, Health and Pharmaceutical Journal $n Eur. Med. Health Pharm. J. $x MED00177703
LZP    __
$c NLK121 $d 20151119 $a NLK 2015-16/vt

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace